Your email has been successfully added to our mailing list.

×
0 0 0 0 -0.0322580645161291 -0.0225806451612903 -0.0403225806451612 -0.0748387096774193
Stock impact report

Hemispherx Announces Data Presentation on the Potential for Ampligen to Improve Cancer Outcomes with Checkpoint Inhibitors

HEMISPHERX BIOPHARMA (HEB) 
NASDAQ:AMEX Investor Relations: hemispherx.net/mobile/investor-relations.php
Company Research Source: GlobeNewswire
MIAMI, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, announced that Pawel Kalinski, MD, vice chairman for translational research and professor of oncology at Roswell Park Cancer Institute, presented data yesterday detailing the role of combination Ampligen® therapy in making the microenvironment of solid tumors more responsive to immuno-oncology agents such as checkpoint inhibitors. Pawel Kalinski, MD, presenting at the Immuno-Oncology Frontiers 2018 Conference The presentation, titled “Sensitizing Cold Tumors to Immunotherapy: Selectivity and Specificity of Systemic and Local Approaches”, took place January 24, 2018 at the Immuno-Oncology Frontiers Conference in Miami, FL. “Increasing the presence of cytotoxic (killer) Show less Read more
Impact Snapshot
Event Time:
HEB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for HEB alerts
Opt-in for
HEB alerts

from News Quantified
Opt-in for
HEB alerts

from News Quantified